-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Xilio Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q3 2024.
- Xilio Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$14.8M, a 15% increase year-over-year.
- Xilio Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$65.1M, a 22.7% increase year-over-year.
- Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$79.1M, a 11.2% increase from 2022.
- Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$89.1M, a 18.8% decline from 2021.
- Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$75M, a 37.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)